🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Relationship Between Circulating Sclerostin and Bone Lesions in Patients With Mastocytosis

Recruitingn/aAges 18 Years - anyAllMedical University of Lublin
NCT06440148 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Mastocytosis is very rare and highly heterogeneous group of disorders, characterized by the accumulation of clonal mast cells which can infiltrate several organs and tissues. Bones are the most frequent localization of systemic mastocytosis. The aim of our research was to explain the potential role of sclerostin in the pathogenesis of bone disease in mastocytosis.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age \> 18 years * Mastocytosis defined according to WHO criteria * Known KIT mutation status Exclusion Criteria: * History of organ transplant * Inability to give informed consent * Pregnancy, Breastfeeding * Vulnerable Patient, defined as: patient with another uncontrolled severe disease; patient under juridical protection
💊

What it tests

  • SCLEROSTIN
📍

Where

1 site
Department of Hematooncology and Bone Marrow Transplantation
Lublin, Poland
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy